Link Biologics strengthens IP position for Link_TSG6 with US patent Notice of Allowance and University of Manchester IP assignment
- Secures long‑term ownership and protection of Link_TSG6, strengthening its global IP position in key markets
- De‑risks development and enhances long‑term value, supporting advancement towards clinical development
London, UK – 6 May 2026 – Link Biologics (“Link” or “the Company”), the biotech company developing first-in-class TSG-6-based therapies that have a unique combination of anti-inflammatory, tissue-protective and tissue-reparative properties, today announces the successful assignment of intellectual property (IP) from the University of Manchester alongside a Notice of Allowance from the United States Patent and Trademark Office (USPTO) covering Link_TSG6 for the treatment of Dry Eye Disease (DED).
